YOSEMITE and RHINE

[1]  Sung Who Park,et al.  Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema , 2020, Scientific Reports.

[2]  Z. Haskova,et al.  Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration , 2020, JAMA ophthalmology.

[3]  S. Fauser,et al.  Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration , 2020, JAMA ophthalmology.

[4]  David F Williams,et al.  Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes , 2020, British Journal of Ophthalmology.

[5]  C. Wykoff,et al.  Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. , 2020, Ophthalmology.

[6]  Sung Who Park,et al.  One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study , 2020, Ophthalmologica.

[7]  P. Sanfilippo,et al.  Clinical Outcomes of a Treat and Extend Regimen with Intravitreal Aflibercept Injections in Patients with Diabetic Macular Edema: Experience in Clinical Practice , 2019, Ophthalmology and Therapy.

[8]  F. Lum,et al.  Treatment Patterns for Diabetic Macular Edema: An Intelligent Research in Sight (IRIS®) Registry Analysis. , 2019, Ophthalmology.

[9]  Jennifer I. Lim,et al.  Diabetic Retinopathy Preferred Practice Pattern®. , 2019, Ophthalmology.

[10]  T. Hong,et al.  Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia , 2019, Diabetes, metabolic syndrome and obesity : targets and therapy.

[11]  C. Wykoff,et al.  Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. , 2019, Ophthalmology.

[12]  David F Williams,et al.  Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States. , 2018, Ophthalmology. Retina.

[13]  S. Kiss,et al.  Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice. , 2018, American journal of ophthalmology.

[14]  Bianca S. Gerendas,et al.  Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA) , 2017, Ophthalmologica.

[15]  C. Klein,et al.  Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases , 2016, EMBO molecular medicine.

[16]  R. Adelman,et al.  Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature , 2016, British Journal of Ophthalmology.

[17]  S. Sivaprasad,et al.  Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion , 2016, Clinical ophthalmology.

[18]  A. Wenzel,et al.  Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study , 2015, British Journal of Ophthalmology.

[19]  P. Kaiser,et al.  Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. , 2015, Ophthalmology.

[20]  Carsten Framme,et al.  TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations , 2015, Retina.

[21]  Jennifer K. Sun,et al.  Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. , 2015, The New England journal of medicine.

[22]  P. Kaiser,et al.  Intravitreal aflibercept for diabetic macular edema. , 2014, Ophthalmology.

[23]  Nader Sheibani,et al.  Diabetes and Retinal Vascular Dysfunction , 2014, Journal of ophthalmic & vision research.

[24]  J. Sorof,et al.  Anti-vascular endothelial growth factor therapy for diabetic macular edema , 2013, Therapeutic advances in endocrinology and metabolism.

[25]  S. Cousens,et al.  Computerized repeating and averaging improve the test-retest variability of ETDRS visual acuity measurements: implications for sensitivity and specificity. , 2011, Investigative ophthalmology & visual science.

[26]  Frank Bretz,et al.  Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests , 2011, Biometrical journal. Biometrische Zeitschrift.

[27]  S. Sivaprasad,et al.  Intersession Repeatability of Visual Acuity, Colour Vision, Contrast Sensitivity, Retinal Sensitivity Thresholds and Retinal Thickness in Mild Diabetic Retinopathy , 2011 .

[28]  Francesco Bandello,et al.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. , 2011, Ophthalmology.

[29]  G. Rubin,et al.  Intersession repeatability of visual acuity scores in age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.

[30]  Beau B. Bruce,et al.  Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. , 2017, Ophthalmology.

[31]  Thomas W. Gardner,et al.  Diabetic Retinopathy and Diabetic Macular Edema. , 2016, Developments in ophthalmology.

[32]  P. Kaiser,et al.  Intravitreal A fl ibercept for Diabetic Macular Edema , 2014 .

[33]  T. Sano,et al.  [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.